CTIS2024-513464-26-00
Recruiting
Phase 1
A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) induction and lenalidomide maintenance in patients with newly diagnosed multiple myeloma (GMMG-HD7) - GMMG-HD7
niversitaetsklinikum Heidelberg AöR0 sites662 target enrollmentJuly 5, 2024
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Multiple Myeloma
- Sponsor
- niversitaetsklinikum Heidelberg AöR
- Enrollment
- 662
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients meeting all of the following criteria will be considered for admission to the trial:, Ability of patient to understand character and individual consequences of the clinical trial., Provide written informed consent (must be available before enrolment in the trial)., Confirmed diagnosis of untreated multiple myeloma requiring systemic therapy., Patient is eligible for high dose therapy and autologous stem cell transplantation., Measurable disease, defined as any quantifiable monoclonal protein value, defined by at least one of the following three measurements:34 • Serum M\-protein \= 10g/l (for IgA \= 5g/l) • Urine light\-chain (M\-protein) of \= 200 mg/24 hours • Serum FLC assay: involved sFLC level \= 10 mg/dl and abnormal sFLC ratio, Age 18 \- 70 years inclusive, WHO performance status 0\-2, Negative pregnancy test at inclusion (females of childbearing potential)., All patients must agree on the requirements regarding the lenalidomide pregnancy prevention plan described in section 6\. For all men and females of childbearing potential: patients must be willing and capable to use adequate contraception during the complete therapy., All patients must • agree to abstain from donating blood while taking lenalidomide and for 28 days following discontinuation of lenalidomide therapy • agree not to share study drug lenalidomide with another person and to return all unused study drug to the investigator or pharmacist
Exclusion Criteria
- •Patients presenting with any of the following criteria will not be included in the trial:, Patients with active, uncontrolled infections, Patients with severe renal insufficiency (Creatinine Clearance \< 30ml/min), Patients with peripheral neuropathy or neuropathic pain, CTC grade 2 or higher (as defined by the NCI Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5\.0\), Patients with a history of active malignancy during the past 5 years with the exception of the following malignancies after curative therapy: basal cell carcinoma of the skin, squamous cell skin carcinoma, stage 0 cervical carcinoma or any in situ malignancy (A history of an early stage malignancy during the past 5 years may be acceptable. In this case the GMMG study office has to be consulted prior to study inclusion.), Patients with acute diffuse infiltrative pulmonary and/or pericardial disease, Autoimmune hemolytic anemia with positive Coombs test or immune thrombocytopenia, Platelet count \< 75 x 10^9/l (Platelet transfusions are not permitted to improve platelet count prior to study inclusion.), Haemoglobin \= 8\.0 g/dl, unless related to myeloma, Absolute neutrophil count (ANC) \< 1\.0 x 10^9/l (the use of colony stimulating factors within 14 days before the test is not allowed), Corrected serum calcium \> 14 mg/dl (\> 3\.5 mmol/l), Patient has known hypersensitivity (or contraindication) to dexamethasone, sucrose histidine (as base and hydrochloride salt), boron, mannitol, and polysorbate 80 or any of the components of study therapy that are not amenable to premedication with steroids or H2 blockers that would prohibit further treatment with these agents., Unable or unwilling to undergo thromboprophylaxis, Pregnancy and lactation, Participation in other clinical trials. This does not include long\-term follow\-up periods without active drug treatment of previous studies during the last 6 months., Prisoners or subjects who are legally institutionalized, or those unwilling or unable to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restrictions., Systemic AL amyloidosis (except for AL amyloidosis of the skin or the bone marrow), Plasma cell leukemia, Previous chemotherapy or radiotherapy during the past 5 years except local radiotherapy in case of local myeloma progression or benign diseases, such as nonmalignant thyroid diseases. (Note: patients may have received a cumulative dose of up to 160 mg of dexamethasone or equivalent as emergency therapy.) Previous therapy due to smouldering myeloma may be acceptable. In this case the GMMG study office has to be consulted prior to inclusion., Severe cardiac dysfunction (NYHA classification III\-IV), ejection fraction \< 40%., Significant hepatic dysfunction (ASAT and/or ALAT \= 3 times normal level and/or serum bilirubin \= 1\.5 times normal level if not due to hereditary abnormalities as Gilbert’s disease), unless related to myeloma., Patients with active or history of hepatitis B or C (Prior hepatitis B may be acceptable if an adequate prophylaxis is being implemented during the course of the study.), HIV positivity
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Trial in patients with newly diagnosed myeloma to evaluate the effect of isatuximab in induction therapy with lenalidomide / bortezomib / dexamethasone and in lenalidomide maintenance treatmentewly diagnosed symptomatic multiple myelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2017-004768-37-DERuprecht-Karls-University Heidelberg, Medical Faculity, represented by University Hospital Heidelberg662
Active, not recruiting
Not Applicable
_PROSTATIC ADENOCARCINOMA WITH HIGH RISK OF RECURRENCE.MedDRA version: 18.1Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2010-022037-29-DEICANCER700
Active, not recruiting
Not Applicable
AFU-GETUG20EUCTR2010-022037-29-SKICANCER700
Active, not recruiting
Not Applicable
Randomized Phase III Trial to evaluate the effect of statins on tumour biology in non-small cell lung cancer. - Neostaton-small cell lung cancerMedDRA version: 9.1Level: LLTClassification code 10025050Term: Lung cancer non-small cell stage IMedDRA version: 9.1Level: LLTClassification code 10025051Term: Lung cancer non-small cell stage IIMedDRA version: 9.1Level: LLTClassification code 10025052Term: Lung cancer non-small cell stage IIIMedDRA version: 9.1Level: LLTClassification code 10025053Term: Lung cancer non-small cell stage IIIAEUCTR2007-000903-14-GBImperial College, London184
Not yet recruiting
Not Applicable
Tauranga Older Persons Comprehensive Assessment TrialACTRN12606000042549Ministry of Health, New Zealand320